natgillin/translations-raw huggingface dataset:
releasing the containers (2) by free fall on the conveyor (4) with simultaneous movement of the pincers (6) in a region of non interference with the containers transferred on the conveyor. 
- < puštanje spremnika (2) slobodnim padom na beskonačnu pomičnu traku (4) uz istovremeno pomicanje kliješta (6) u predjelu u kojemu one ne smetaju prenošenju spremnika na beskonačnu pomičnu traku.
calendering the paper. 
(c) -kalendiranje papira.
The pharmaceutical composition of claim 7 for use in a method of treating an immune disease. 
Farmaceutska kompozicija bilo kojeg od patentnih zahtjeva 11-14 za primjenu u metodi liječenja imunološke bolesti.
Compression Cylinder (psi) 
Comp: kompresijski cilindar
V is oxygen or sulfur; or a salt thereof. 
V je kisik ili sumpor; ili njegova sol.
Cy is phenyl optionally substituted with one, two, or three substituent groups independently selected from —Cl, —F, C1-3alkyl and CN. 
Cy je fenil koji je opcijski supstituiran s jednom, dvije ili tri supstituentske skupine neovisno odabrane od sljedećih: -CL, -F, C,.3-alkil i CN.
After stirring a further 10 minutes the solution was decanted from excess zinc, the methanol evaporated and the aqueous acid residue washed with toluene (100 ml), basified with concentrated ammonia and extracted with methylene chloride (2 x 100 ml). 
Nakon miješanja daljnjih 10 minuta, otopina se oddekantira od viška cinka, metanol se ispari i vodena kiselina iz ostatka se ispere s toluolom (100 ml), zaalkali se s koncentriranim amonijakom i ekstrahira s metilenkloridom (2 x 100 ml).
A compound in accord with Formula I: 
Spoj sa formulom II: naznačen time da
A pharmaceutical composition comprising an antibody according to any one of claims 1 to 18, in combination with one or more of a pharmaceutically acceptable excipient, diluent or carrier. A pharmaceutical composition according to claim 24, additionally comprising other active ingredients. 
Farmaceutski pripravak koji sadrži antitijelo prema bilo kojem od patentnih zahtjeva od 1 do 3, u kombinaciji sa jednim ili više farmaceutski prihvatljivim ekscipientom, otapalom ili nosačem; naznačen time da farmaceutski pripravak sadrži po izboru sadrži druge aktivne sastojke.
As shown in FIG. 2, and with further reference to FIG. 3 (left side), system 10 includes a receiver 30 adapted to accept and receive the end 22 of bottle 20 with opening 26 . 
Kako je prikazano na slici 2, i s pozivom na sliku 3 (lijeva strana), sustav 10 obuhvaća nosač 30 koji prihvaća 1 prima kraj 22 boce 20 s otvorom 26.
Pressurizing the feed material to a predetermined process pressure of at least 150 bar; 
– stlačivanju dovodnog materijala do zadanog tlaka obrade od najmanje 150 bara (15 MPa);
The isolated nucleic acid of claim 8, wherein the anti-LOXL2 antibody comprises a variable heavy chain of SEQ ID NO: 27 and a variable light chain of SEQ ID NO: 31. 
Protutijelo ili njegov za antigen vezni fragment prema zahtjevu 6, gdje varijabilni teški lanac obuhvaća SEQ ID NO:27.
X represents CH2, O, S, S(O), SO2 or NH, such that when X represents NH, the nitrogen atom may be optionally substituted with R6, C(O)R6, or SO2R6, wherein: 
X predstavlja CH2, O, S, S(O), SO2 ili NH, tako da kada X predstavlja NH, atom dušika može po izboru biti supstituiran s R6, C(O)R6, ili SO2R6, gdje:
Number of Animals Time 
Broj međunarodne objave:
Apparatus according to claim 3, wherein the plurality of anvils are provided as a pair of anvils on either of the mounting members and an intermediate third roller on the other of the mounting members. 
Uređaj prema zahtjevu 3, gdje postoji niz nakovanja kao parovi nakovanja na bilo kojem od ugradbenih članova i srednji treći valjak na drugom od ugradbenih članova.
only one of R7-R12 is different from hydrogen and the substituent is selected from the group consisting of hydrogen, methyl, fluoro, chloro or methoxy; 
Samo jedan R"-R'* je različit od vodika, a supstitiuent se bira iz grupe koja se sastoji iz vodika, metila, fluora, klora ili metoksi
The agent for use according to claim 4, wherein the agent is for treating tubulointerstitial nephritis. 
Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 4, naznačen time što je sredstvo za liječenje tubulointersticijskog nefritisa.
oxidizing the compound of Formula LXXII to give a compound of Formula LXXIII; 
Formula LXAIII f. reakciju spoja Formule LXXIII sa spojem Formule LXXTV,
From Fig. 5 it is clear that the wall element 2 is rectangular. 
Sa sl.5 vidljivo je da je zidni element pravokutan.
The use of any one of claims 9 to 13, wherein the antigen-binding fragment is an scFv and the heavy chain variable region and the light chain variable region are linked by the sequence of SEQ ID NO: 181. 
Fragment koji se veže na antigen prema zahtjevu 30, naznačen time, da fragment je scFv, te time, da su varijabilno područje jakog lanca i varijabilno područje slabog lanca spojeni putem sekvence od SEQ ID NO:181.
Transform-based decoder configured to decode a transform coefficient block using an apparatus (150) for decoding a significance map indicating positions of significant transform coefficients within the transform coefficient block from a data stream, according to any of claims 1 to 9, and to apply (152) a transform from spectral domain to spatial domain to the transform coefficient block. 
Dekoder na bazi transformacije, naznačen time, da je konfiguriran za dekodiranje bloka koeficijenata transformacije uporabom uređaja (150) za dekodiranje signifikacijske mape iz protoka podataka, koja prikazuje pozicije sigmifikantnih koeficijenata transformacije unutar bloka koeficijenata transformacije, prema bilo kojem od zahtjeva 1 do 9, te za izvođenje (152) transformacije iz spektralne domene u prostornu domenu u bloku koeficijenata transformacije.
inserting the starting liquid, the partly AX-REED treated liquid or the AX-REED liquid into the chamber for the starting liquid or the AX-REED liquid; and 
I. - umetanje početne tekućine, djelomično obrađene tekućine s AX-REED ili AX-REED tekućine u komoru za početnu tekućinu ili tekućinu AX-REED; i
other elements, expressed in oxide form: <1.00%, Y2O3/SiO2 ratio being between 0.80 and 2.00, and a tetragonal phase representing between 60 and 90% of the mass of zirconia, the remainder being in the monoclinic form. 
1.00 do 2.00% druge elementa, izražene u obliku oksida: < 1.00%, omjer Y2O3/SiO, se nalazi između 0.80 i 2.00, a tetragonska faza predstavlja između 60 i 90% mase cirkonija, te se ostatak nalazi u monoklinskom obliku.
As can be seen especially from figure 12, the foil member 5 can be wrapped (see reference 27) over the rim of the capsule. 
Kao što se može naročito vidjeti iz slike 12, element od folije 5 može biti pokidan (vidi oznaku 27) na rubu čahure.
the fourth polypeptide chain comprises, in the N-terminal to C-terminal direction: 
IV. četvrti polipeptidni lanac sadrži, u smjeru od N-terminalnog kraja do C-terminalnog kraja:
Glucose isomerase for use according to claim 4, wherein the coating of the capsules, tablets, pellets, granules, micro- or mini-tablets and dragees is selected from cellulose acetate phthalate, cellulose derivatives, shellac, polyvinylpyrrolidone derivatives, acrylic acid, polyacrylic acid derivatives and polymethyl methacrylate. 
Glukoza izomeraze za uporabu u skladu sa zahtjevom 12, naznačena time, što premazivanje kapsula, tableta, pilula, granula, mikro-ili mini-tableta i dražeja je odabrano iz celuloze acetat ftalata, derivata celuloze, šelaka, derivata polivinilpirolidona, akrilne kiseline, derivata poliakrilne kiseline i polimetila metakrilata.
Accordingly, part of the oligofructose in the second and third embodiments of the invention is replaced by resistant maltodextrin. 
Slijedom toga, dio oligofruktoze u drugoj i trećoj varijanti zamjenjuje se rezistentnim maltodekstrinom.
Most preferably, the water miscible organic solvent is at least one of acetone, methanol, ethanol, isopropanol, or acetonitrile. 
Najpoželjnije, organsko otapalo koje se miješa s vodom je najmanje jedno između acetona, metanola, etanola, izopropanola, ili acetonitrila.
The KLB modulator for use according to claim 7, wherein the anti-KLB antibody is a monoclonal antibody. 
Uporaba prema zahtjevu 7 ili zahtjevu 8, naznačena time, da protutijelo anti-KLf je monoklonsko protutijelo.
The process of claim 1 further comprising the step of treating said second mixture with a second base, resulting in a dynamic resolution of said second mixture, in which said B-isomer of Compound 17C is converted to a-isomer of Compound 17C, and a-isomer of Compound 17C is precipitated to produce Compound 17. 
Postupak u skladu s patentnim zahtjevom 36, naznačen time što se dodatno sastoji u koraku obrade navedene druge smjese drugom bazom, što uzrokuje dinamičko razdvajanje navedene druge smjese, u kojoj navedeni f3- izomer Spoja 17C se prevodi u a-izomer Spoja 17C, te se a-izomer Spoja 17C istaloži kako bi se dobilo Spoj 17.
or a pharmaceutically acceptable salt of such compound. 
CN, pri čemu su R? i R" kao što je prethodno definirano; ili farmaceutski prihvatljiva sol navedenog spoja.
the anti-KIR antibody and anti-PD-1 antibody are for being administered sequentially; or 
(d) anti-KIR antitijelo i anti-PD-I antitijelo se administriraju sekvencijalno; ili
The present invention also relates to a cloning or expression vector comprising one or more DNA sequences of the present invention. 
Vektor kloniranja ili ekspresije, naznačen time da sadrži jednu ili više DNA sekvenci prema zahtjevu 13.
A compound for use according to claim 18 wherein the disorder mediated by inappropriate PI3-kinase activity is asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), viral respiratory tract infections, viral exacerbation of respiratory diseases, aspergillosis, leishmaniasis, allergic rhinitis, atopic dermatitis, rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, thrombosis, atherosclerosis, hematologic malignancy, neurodegenerative disease, pancreatitis, multiorgan failure, kidney disease, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection, lung injury, pain associated with rheumatoid arthritis or osteoarthritis, back pain, general inflammatory pain, post hepatic neuralgia, diabetic neuropathy, inflammatory neuropathic pain (trauma), trigeminal neuralgia or Central pain. 
Kombinacija namijenjena upotrebi u skladu s patentnim zahtjevom 11, naznačena time što je poremećaj uzrokovan neodgovarajućom aktivnošću PI3-kinaze astma, kronična opstruktivna plućna bolest (COPD), idiopatska plućna fibroza (IPF), virusne infekcije dišnog sustava, virusne komplikacije respiratornih bolesti, aspergiloza, lišmenijaza, alergičko rinitis, atopični dermatitis, reumatoidni artritis, multipla skleroza, upalna bolest crijeva, tromboza, ateroskleroza, hematološki zloćudni tumor, neurodegenerativna bolest, pankreatitis, multiorganska insuficijencija, bolest bubrega, agregacija trombocita, rak, pokretljivost sperme, odbacivanje transplantata, odbacivanje presatka, ozljeda pluća, bol povezana s reumatoidnim artritisom ili osteoartritisom, bol u leđima, opća upalna bol, posthepatična neuralgija, dijabetična neuropatija, upalna neuropatska bol (trauma), trigeminalna neuralgija ili centralna bol.
a first antibody or combination of antibodies which recognise said target polypeptide wherein the first antibody is directed against an epitope located within amino acids 1 to 16 of AB40 and AB42, wherein the first antibody is prebound to a solid support, 
prvo protutijelo ili kombinacija protutijela koja prepoznaje navedeni ciljni polipeptid, gdje je prvo protutijelo usmjereno protiv epitopa koji se nalazi kod aminokiselina 1 do 16 u AB40 i AB42, a prvo protutijelo je prethodno vezano na čvrsti nosač,
More specifically, the neurodevelopmental disease is caused by a reduction of MeCP2 expression or by an impaired function of MeCP2, as described above. Particularly, the neurodevelopmental disease is Rett syndrome, as described above. 
Uporaba prema zahtjevu 12, naznačena time, da je ncurorazvijajuća bolest očekivana uslijod redukcije cksprosije MeCP2 ili uslijed oslabljene funkcije MeCP2, posebno kada je neurorazvijajuća bolest Rett-sindrom.
A pharmaceutical composition comprising a compound of the formula I, and/or a pharmaceutically acceptable salt thereof, as active ingredient together with a pharmaceutically acceptable diluent or carrier. 
Farmaceutski sastav, naznačen time, da sadrži spoj prema bilo kojem zahtjevu 1 do 10, u slobodnom bazičnom obliku ili u obliku farmaceutski prihvatljive dodatne kiselinske soli, s pripojenim farmaceutskim nosačem ili razrjeđivačem.
The puller assembly of claim 3 wherein said plurality of arc-shaped sections consists of three sections. 
Sklop ekstraktora prema patentnom zahtjevu 3, naznačen time, što se više zakrivljenih sekcija (44-46) sastoji od tri sekcije.
The method of claim 8 wherein the respiratory distress is the infant Respiratory Distress Syndrome (RDS). 
Farmaceutski komplet za upotrebu kako je prijavljen u patentnom zahtjevu 1, naznačeno time da respiratorni distresni sindrom jest dječji respiratorni distresni sindrom (IRDS).
recovering the antibody molecule from the cell culture. 
(c) dobivanje molekule protutijela iz stanične kulture.
An analytical sample of the named compound was recrystallized from hot ethyl acetate-hexane (elemental analysis calculated: 62.58% C; 3.94% H; 23.10% Cl; found: 62.66% C; 4.02% H; 23.22% CI). 
Analitički uzorak imenovanog spoja se rekristalizira iz vrućeg etilacetatheksana (elementarna anliza izrač.: 62.58% C; 3.94% Hr; 23.10% CI; nađeno: 62.66% C; 4.02% H; 23.22% CI).
substitution with Glu, Val, Ala, etc.) 
supstitucija s Glu, Val, Ala i t.d.)
The composition of paragraph 22, wherein the composition further comprises a peroxide-containing additive, for example, di-cumyl peroxide or 1,1-Di(tert-butylperoxy)-3,3,5-trimethylcyclohexane, optionally wherein the peroxide-containing additive is present in the coating. 
Smjesa u skladu s patentnim zahtjevom 12, naznačena time što navedena smjesa dodatno sadrži aditiv koji sadrži peroksid, primjerice dikumil peroksid ili 1,1-di(tert-butilperoksi)-3,3,5-trimetilcikloheksan, gdje je izborno aditiv koji sadrži peroksid prisutan u oblozi.
A CAR according to paras 1 to 6 wherein the spacer lacks the serine /threonine-rich stalk of LNGFR. 
CAR prema patentnim zahtjevima 1 do 4 naznačen time što razmaknici nedostaje stabljiku LNGFR bogata serinom/treoninom.
The oligomer according to any one of embodiments 1 - 13, wherein the third region comprises a non-nucleotide moiety, such as a conjugate group, such as a sterol, for example cholesterol, or a carbohydrate, such as GalNac/GalNac cluster. 
Oligomerni spoj prema bilo kojem od patentnih zahtjeva 1 do 11, naznačen time, da treća regija obuhvaća ne-nukleotidnu aktivnu tvar poput skupine konjugata kao što je sterol, primjerice kolesterol, ili ugljikohidrat poput klastera GalNac/GalNac.
The anti-CTLA-4 antibody and 2'-deoxy-2',2'-difluorocytidine monohydrochloride (B-isomer), or pharmaceutically acceptable salt, solvate, or hydrate thereof, for the use according to any one of Claims 1 to 13, wherein 2'-deoxy-2',2'-difluorocytidine nionohydrochloride (B-isomer), or pharmaceutically acceptable salt, solvate, or hydrate thereof, is administered via IV infusion. 
Anti-CTLA-4 antitijelo i 4'-Demetilpipodofilotoksin 9-[4,6-O-(R)-etiliden-B-D-glukopiranozid], 4'-(dihidrogen fosfat) ili njegova farmaceutski prihvatljiva sol, solvat, ili hidrat, za primjenu prema bilo kojem od patentnih zahtjeva 1 do 13, gdje navedeni anti-CTLA4 je administriran otprilike svaka tri tjedna.
comparing the amount of said immunologic complex to a normal control value, wherein an increase in the amount of said complex compared to a normal control value indicates that said patient is suffering from or is at risk of developing an amyloid-associated disease or condition. 
(6) uspoređivanja količine navedenog imunološkog kompleksa s normalnom kontrolnom vrijednošću, gdje povećanje količine navedenog kompleksa u usporedbi s normalnom kontrolnom vrijednošću ukazuje da subjekt boluje od ili je u opasnosti da mu se pojavi glaukom, optički neuritis ili retikularna distrofija.
A compound as claimed in any one of claims 1, 6 or 8, or a pharmaceutically acceptable salt or ester thereof, or a pharmaceutical composition as claimed in claim 2 or 9, wherein n is 1, R3 is H and one of R4 and R5 is methyl. 
Spoj prema zahtjevima 1, 6 ili 8, ili njegova farmaceutski prihvatljiva sol ili njegov farmaceutski prihvatljiv ester, ili farmaceutski sastav prema zahtjevu 2 ili 9, naznačen(a) time, da nje 11 R3 je H ijedan od R4 1 R5 je metil.
obtaining nucleic acids from said B cells, optionally, amplification of nucleic acid sequences encoding immunoglobulin heavy chain variable regions in said sample, at least partial sequencing of essentially all obtained nucleic acids of step b) or the amplification products of step c), 
Cc) po izboru, amplifikacija sekvenci nukleinske kiseline koje kodiraju varijabilne regije teškog lanca imunoglobulina u navedenom uzorku, d) najmanje djelomično sekvenciranje uglavnom svih dobivenih nukleinskih kiselina iz koraka b) ili proizvoda amplifikacije iz koraka c),
Method according to claim 11, characterized in that the pivot point of the pivoted lever is fixed by forcing the secondary pivoting arm against a fixed stop. 
Postupak prema zahtjevu 11, naznačen time, da se učvršćuje stožerna točka (12a, 12b) stožerne poluge (11) pomoću prisiljavanja pomoćne stožerne ručice (15) prema učvršćenom zaporu (18a, 18b).
The topical composition according to claim 7, wherein the pharmaceutically acceptable carrier is at least one of a cream and an ointment comprising stearic acid, stearyl alcohol, cetyl alcohol, glycerin, and water, the topical composition having a physiologically acceptable pH. 
Topička kompozicija za uporabu prema patentnom zahtjevu 4, naznačeno time da je farmaceutski prihvatljiv nosač najmanje jedno od krema i mast koji sadrži stearinsku kiselinu, stearilni alkohol, cetilni alkohol, glicerin, i vodu, topička kompozicija ima fiziološki prihvatljiv pH.
A compound of Formula I: or a pharmaceutically acceptable salt or solvate thereof, wherein: 
[image] ili njegova farmaceutski prihvatljiva sol ili njegov solvat, pri čemu:
A composition comprising a CD20-binding protein consisting essentially of the amino acid sequence shown in SEQ ID NO: 4 or SEQ ID NO: 12; and 
ili da regija za vezivanje imunoglobulinskog tipa sadrži sljedove amino kiselina 1-119 sa SEQ ID NO:5, kao što citotoksični protein sadrži polipeptidni slijed SEQ ID NO:5.
The process of claim 1 in which the inwardly convergent flow vectors at the melt surface show a speed up to approximately 2 m/s. 
gdje prema unutra usmjereni konvergentni vektori tečenja na površini taline pogodno imaju brzinu do 2 m/s;
An aqueous pharmaceutical composition comprising insulin glargine in a concentration of 300 U/mL being equimolar to 300 IU human insulin for use in providing a peakless long acting basal insulin in the treatment of Type I and Type II Diabetes Mellitus in a patient. 
Vodeni farmaceutski pripravak sa pH između 3.4 i 4.6 koji sadrži inzulin glargin naznačen time da je za uporabu u postupku za osiguravanje dugodjelujućeg bazalnog inzulina bez vrhunca u liječenju dijabetes melitusa tipa I i tipa II, pri čemu pripravak sadrži 270 - 330 U/mL inzulin glargina.
A combination according to 1 or 2 characterised in that the active ingredients (a) and (b) form part of a single pharmaceutical composition. 
Kombinacija sukladno bilo kojem prethodnom patentnom zahtjevu, naznačena time, da djelatni sastojci (a) i <b) čine jedinstveni farmaceutski pripravak.
further comprising at least one administration of Salmonella of D group between about 3 and about 10 weeks following the administration of the at least one inactivated Salmonella of B group. 
Uporaba prema zahtjevu 9, naznačena time, da: nadalje obuhvaća najmanje jednu primjenu bakterije Salmonella skupine D u vremenskom razmaku od otprilike 2 tjedna do otprilike 18 tjedana, koja slijedi nakon davanja najmanje jedne neaktivirane bakterije Salmonella skupine B.
The antikine antibody may bind to at least one determinant within CC receptor binding residues of a CC chemokine. 
Monoklonsko protutijelo, ili njegov fragment koji veže antigen, u skladu s patentnim zahtjevom 1, naznačeno time, da se veže na najmanje jednu determinantu unutar veznog ostatka CC receptora CC kemokina.
The compound according to claim 5 wherein m=1 n=1 and Q=CH2 sub structure III. 
Spoj u skladu s patentnim zahtjevom 6, gdje m = 1, n = 1, a Q je CH2.
A method of treating neuropathic pain, comprising administering to a subject in need thereof a therapeutically effective amount of a compound selected from the group consisting (2S)-(-)-N-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide; and pharmaceutically acceptable salts thereof. 
Spoj, naznačen time, da je izabran iz skupine koja se sastoji od (25)-(-)-N-(6-klor-2,3-dihidro-benzo[1,4]dioksin-2- ilmetil)-sulfamida; i njegove farmaceutski prihvatljive soli za upotrebu kod liječenja boli.
a drawing pump connected to said suction tube, said drawing pump being arranged to suck water from the suction tube and transport the water through the circulation ducts to said plurality of positions provided in said jetted tub; 
- barem jednu napojnu pumpu (23') spojenu na navedenu usisnu cijev (25'), navedena barem jedna napojna pumpa (23) je postavljena da usisava vodu iz usisne cijevi (25'); naznačen time da ima
The device according to any of the preceding claims, wherein one of the jaw members (6, 7) comprising means for injecting a liquid into an inserted capsule and the respectively other jaw member comprises means for draining a produced beverage from an inserted capsule (24). 
Uređaj u skladu s bilo kojim od prethodnih patentnih zahtjeva, kod kojega jedan od clemenata čeljusti (6, 7) ima sredstva za injektiranje tekućine u umetnutu čahuru, a odgovarajući drugi element čahure ima sredstva za odvođenje proizvedenog napitka iz umetnute čahure (24),
Electric conductors 60 extend through a through conduit 32 to connect receiving antenna 42 and transmitting antenna 44 to electronic circuit 4 . FIGS. 
Električni vodiči 60 se pružaju cijelom duljinom voda 32 da povežu prijemnu antenu 42 i predajnu antenu 44 na elektronski krug 4.
The casing may also include an anti-tack agent such as talc, silica or glyceryl monostearate. 
Kućište može također uključivati sredstvo protiv lijepljenja kao što je talk, silicij ii gliceril monostearat.
A fusion protein comprising the polypeptide of claim 1 joined to a heterologous sequence. 
Fuzijski protein naznačen time da sadrži izolirani topivi CIORF32 polipeptid ektodomene sparen na sekvencu proteina ne-CIORF32.
According to the experimental studies, water content in the 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-piperidine monohydrochloride crystals can reach up to 6±0.5%. 
Prema eksperimentalnim studijama, sadržaj vode u kristalima 1-[3-[3-(4-klorfenil)propoksilpropil]-piperidin monoklorida dosiže do 6 + 0,5 %.
The waterproof panel according to claim 27, wherein at least one of the waterproof membranes is made of a geosynthetic material. 
Vodonepropusna ploča (14; 14A) u skladu s patentnim zahtjevom 28 ili 29, naznačena time, da je najmanje jedna od vodonepropusnih membrana (16, 17) načinjena od geosintetskog materijala.
the method is carried out without seeding zofenopril calcium form A; and/or 
(vi) postupak je izveden bez ubacivanja klica kristala zofenopril kalcija oblika A; i/ili
The known incorporation of biostimulants into the soil by means of a separate working step, however, has several drawbacks. Namely, the biostimulants should be added in extremely small quantities. 
Pri tome poznato unašanje biostimulatora u tlo odvojenim postupkom ima neke nedostatke, Biostimulatore je naime potrebno dodavati u razmjerno izvanredno malim količinama.